InvestSMART

Radiopharm Theranostics Limited (ASX: RAD) - Announcements

- Current share price for RAD : $0.012

ASX company news and announcements for Radiopharm Theranostics Limited (RAD) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Radiopharm Theranostics Limited (RAD) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Radiopharm Theranostics Limited (RAD), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Radiopharm Theranostics Limited (RAD)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$52 Application for quotation of securities - RAD 28 Aug 2024 11:41AM $0.033 $0.012 fallen by 63.64%
$52 Ceasing to be a substantial holder 27 Aug 2024 6:03PM $0.034 $0.012 fallen by 64.71%
$52 Ceasing to be a substantial holder 27 Aug 2024 12:35PM $0.034 $0.012 fallen by 64.71%
$52 RAD increases ownership in Radiopharm Ventures to 75% 26 Aug 2024 8:39AM $0.034 $0.012 fallen by 64.71%
$52 Becoming a substantial holder 26 Aug 2024 8:08AM $0.034 $0.012 fallen by 64.71%
$52 Becoming a substantial holder 23 Aug 2024 6:26PM $0.034 $0.012 fallen by 64.71%
$52 Change in substantial holding 23 Aug 2024 6:23PM $0.034 $0.012 fallen by 64.71%
$52 Change in substantial holding 23 Aug 2024 4:56PM $0.034 $0.012 fallen by 64.71%
$52 Notice Under Section 708A 23 Aug 2024 4:25PM $0.034 $0.012 fallen by 64.71%
$52 Notification regarding unquoted securities - RAD 23 Aug 2024 4:24PM $0.034 $0.012 fallen by 64.71%
$52 Application for quotation of securities - RAD 23 Aug 2024 4:17PM $0.034 $0.012 fallen by 64.71%
$52 Notice Under Section 708A 21 Aug 2024 4:50PM $0.035 $0.012 fallen by 65.22%
$52 Application for quotation of securities - RAD 21 Aug 2024 4:47PM $0.035 $0.012 fallen by 65.22%
$52 Notice Under Section 708A 21 Aug 2024 9:44AM $0.036 $0.012 fallen by 66.67%
$52 Application for quotation of securities - RAD 21 Aug 2024 9:42AM $0.036 $0.012 fallen by 66.67%
$52 Dr Dimitris Voliotis appointed Chief Medical Officer 20 Aug 2024 9:07AM $0.037 $0.012 fallen by 67.57%
$52 A$70m capital raising & Lantheus investment approved at EGM 14 Aug 2024 11:46AM $0.033 $0.012 fallen by 63.64%
$52 Results of Extraordinary General Meeting 14 Aug 2024 11:35AM $0.033 $0.012 fallen by 63.64%
$52 Presentation to Extraordinary General Meeting 14 Aug 2024 8:18AM $0.032 $0.012 fallen by 62.50%
$52 Update - Proposed issue of securities - RAD 9 Aug 2024 4:48PM $0.032 $0.012 fallen by 62.50%
$52 Update - Proposed issue of securities - RAD 9 Aug 2024 4:39PM $0.032 $0.012 fallen by 62.50%
$52 Prospectus 9 Aug 2024 12:34PM $0.032 $0.012 fallen by 62.50%
$52 Radiopharm receives US$2.0 M payment from Lantheus 5 Aug 2024 8:52AM $0.035 $0.012 fallen by 65.71%
$52 Quarterly Activities/Appendix 4C Cash Flow Report 31 Jul 2024 9:42AM $0.036 $0.012 fallen by 66.67%
$52 Radiopharm targets Nasdaq Listing by end of 2024 26 Jul 2024 11:10AM $0.036 $0.012 fallen by 66.67%

176 - 200 of 612 results

Page 8 of 25

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.